The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
HLA-B*13:01 and the Dapsone Hypersensitivity Syndrome
Open accessAbstract
BACKGROUND: Dapsone is used in the treatment of infections and inflammatory diseases. The dapsone hypersensitivity syndrome, which is associated with a reported mortality of 9.9%, develops in about 0.5 to 3.6% of persons treated with the drug. Currently, no tests are available to predict the risk of the dapsone hypersensitivity syndrome. METHODS: We performed a genomewide association study involving 872 participants who had received dapsone as part of multidrug therapy for leprosy (39 participants with the dapsone hypersensitivity syndrome and 833 controls), using log-additive tests of single-nucleotide polymorphisms (SNPs) and imputed HLA molecules. For a replication analysis, we genotyped 24 SNPs in an additional 31 participants with the dapsone hypersensitivity syndrome and 1089 controls and performed next-generation sequencing for HLA-B and HLA-C typing at four-digit resolution in an independent series of 37 participants with the dapsone hypersensitivity syndrome and 201 controls. RESULTS: Genomewide association analysis showed that SNP rs2844573, located between the HLA-B and MICA loci, was significantly associated with the dapsone hypersensitivity syndrome among patients with leprosy (odds ratio, 6.18; P=3.84×10(-13)). HLA-B*13:01 was confirmed to be a risk factor for the dapsone hypersensitivity syndrome (odds ratio, 20.53; P=6.84×10(-25)). The presence of HLA-B*13:01 had a sensitivity of 85.5% and a specificity of 85.7% as a predictor of the dapsone hypersensitivity syndrome, and its absence was associated with a reduction in risk by a factor of 7 (from 1.4% to 0.2%). HLA-B*13:01 is present in about 2 to 20% of Chinese persons, 1.5% of Japanese persons, 1 to 12% of Indians, and 2 to 4% of Southeast Asians but is largely absent in Europeans and Africans. CONCLUSIONS: HLA-B*13:01 was associated with the development of the dapsone hypersensitivity syndrome among patients with leprosy. (Funded by the National Natural Science Foundation of China and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Browning, S. R., & Browning, B. L. (2007) · The American Journal of Human Genetics · doi:10.1086/521987 · Cited by 3,210
A marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
Study, T. I. H. C. (2010) · Science · doi:10.1126/science.1195271 · Cited by 1,171
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavičiūtė, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., de Bakker, P. I. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013297 · Cited by 925
Self-citationde Bakker, P. I. W., McVean, G., Sabeti, P. C., Miretti, M. M., Green, T., Marchini, J., Ke, X., Monsuur, A. J., Whittaker, P., Delgado, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1885 · Cited by 766
Gonzalez-Galarza, F. F., Christmas, S., Middleton, D., & Jones, A. R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1128 · Cited by 724
Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan
Chen, P., Lin, J.-J., Lu, C.-S., Ong, C.-T., Hsieh, P. F., Yang, C.-C., Tai, C.-T., Wu, S.-L., Lu, C.-H., Hsu, Y.-C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009717 · Cited by 711
Immune self-reactivity triggered by drug-modified HLA-peptide repertoire
Illing, P. T., Vivian, J. P., Dudek, N. L., Kostenko, L., Chen, Z., Bharadwaj, M., Miles, J. J., Kjer-Nielsen, L., Gras, S., Williamson, N. A., et al. (2012) · Nature · doi:10.1038/nature11147 · Cited by 696
Cao, K., Hollenbach, J., Shi, X., Shi, W., Chopek, M., & Fernández-Viña, M. A. (2001) · Human Immunology · doi:10.1016/s0198-8859(01)00298-1 · Cited by 465
Dapsone and sulfones in dermatology: Overview and update
Zhu, Y. I., & Stiller, M. J. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.114733 · Cited by 441
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci
Bei, J.-X., Li, Y., Jia, W.-H., Feng, B.-J., Zhou, G., Chen, L.-Z., Feng, Q.-S., Low, H.-Q., Zhang, H., He, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.601 · Cited by 410
Self-citationNext-generation sequencing for HLA typing of class I loci
Erlich, R., Jia, X., Anderson, S. T., Banks, E., Gao, X., Carrington, M. N., Gupta, N., DePristo, M. A., Henn, M. R., Lennon, N. J., et al. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-42 · Cited by 143
Self-citationYang, G., Deng, Y. ‐., Hu, S., Wu, D. ‐., Li, S. B., Zhu, J., Zhu, B., & Liu, Y. (2006) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00529.x · Cited by 64
Self-citationShi, L., Xu, S., Ohashi, J., Sun, H., Yu, J., Huang, X., Tao, Y., Yu, L., Horai, S., Chu, J., et al. (2005) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00526.x · Cited by 43
Amino acid 95 causes strong alteration of peptide position PΩ in HLA-B*41 variants
Bade‐Doeding, C., DeLuca, D. S., Seltsam, A. W., Blasczyk, R., & Eiz‐Vesper, B. (2007) · Immunogenetics · doi:10.1007/s00251-007-0197-7 · Cited by 25
Cited by
Drug allergy: A 2022 practice parameter update
Khan, D. A., Banerji, A., Blumenthal, K. G., Phillips, E. J., Solensky, R., White, A. A., Bernstein, J. A., Chu, D. K., Ellis, A. K., Golden, D. B. K., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.08.028 · Cited by 563
Self-citationPharmacogenomics: current status and future perspectives
Pirmohamed, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00572-8 · Cited by 351
Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions
Wang, C.-W., Yang, L.-Y., Chen, C.-B., Ho, H.-C., Hung, S.-I., Yang, C.-H., Chang, C.-J., Su, S.-C., Hui, R. C.-Y., Chin, S.-W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93349 · Cited by 289
Self-citationCho, Y.-T., Yang, C.-W., & Chu, C.-Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061243 · Cited by 286
Metadata
- Authors
- Zhang, F.-R., Liu, H., Irwanto, A., Fu, X.-A., Li, Y., Yu, G.-Q., Yu, Y.-X., Chen, M.-F., Low, H.-Q., Li, J.-H., Bao, F.-F., Foo, J.-N., Bei, J.-X., Jia, X.-M., Liu, J., Liany, H., Wang, N., Niu, G.-Y., Wang, Z.-Z., Shi, B.-Q., Tian, H.-Q., Liu, H.-X., Ma, S.-S., Zhou, Y., You, J.-B., Yang, Q., Wang, C., Chu, T.-S., Liu, D.-C., Yu, X.-L., Sun, Y.-H., Ning, Y., Wei, Z.-H., Chen, S.-L., Chen, X.-C., Zhang, Z.-X., Liu, Y.-X., Pulit, S. L., Wu, W.-B., Zheng, Z.-Y., Yang, R.-D., Long, H., Liu, Z.-S., Wang, J.-Q., Li, M., Zhang, L.-H., Wang, H., Wang, L.-M., Xiao, P., Li, J.-L., Huang, Z.-M., Huang, J.-X., Li, Z., Liu, J., Xiong, L., Yang, J., Wang, X.-D., Yu, D.-B., Lu, X.-M., Zhou, G.-Z., Yan, L.-B., Shen, J.-P., Zhang, G.-C., Zeng, Y.-X., de Bakker, P. I. W., Chen, S.-M., & Liu, J.-J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-24
- Volume
- 369
- Issue
- 17
- Pages
- 1620-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2092786402
- Cited by
- 310
- References
- 16
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.